YOLFTbeta
Xbrane Biopharma AB

Xbrane Biopharma AB

XBRANE · ST · Healthcare / Biotechnology

11.45SEK-0.25 (-2.14%)

Price History

Full chart

Market Stats

Previous Close11.70
Open11.80
Day Range11.20 – 12.25
52-Week Range5.42 – 35.05
Volume53.80K
Market Cap276.11M
P/E (TTM)0.00
Forward P/E3.26
EPS-3.28
Dividend Yield0.00%
Beta0.78
50-Day Avg10.12
200-Day Avg9.67

About

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar targeting CD38 for the treatment of multiple myeloma. The company has a strategic partnership with JOINN Biologics US Inc. to provide customized development services for Xdarzane, Xbrane´s biosimilar candidate referencing Darzalex. The company was incorporated in 2008 and is headquartered in Solna, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Martin Amark
  • Employees29
  • HeadquartersScheeles väg 5, Solna, Sweden, 171 65, Sweden
  • Websitehttps://www.xbrane.com

Leadership

  • Mr. Martin AmarkChief Executive Officer · b. 1980
  • Mr. Siavash BashiriCOO, Head of Biosimilars & Deputy CEO · b. 1983
  • Associate Prof. Jan-Willem De GierCo-Founder
  • Dr. Samuel Wagner Ph.D.Co-Founder & Member of Scientific Advisory Board
  • Ms. Jane BenyaminInterim CFO & Head of IR · b. 1979
  • Mr. Anders WallstromHead of Technical Operations · b. 1976
  • Mr. Bjorn LagerHead of Quality Assurance · b. 1980

Financials

Income Statement

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue991.08K189.52K189.63K433.47K2.49M20.77M112.95M600.00K6.82M11.53M57.62M238.73M198.70M152.35M
Growth (%)--80.88%+0.05%+128.59%+474.46%+734.14%+443.80%-99.47%+1036.83%+69.08%+399.59%+314.33%-16.77%-23.32%
Cost of Revenue1.25M98.57K-256.62K6.62M15.83M15.91M18.27M4.37M12.22M16.58M203.34M18.23M72.79M
Gross Profit-254.18K90.95K189.63K176.85K-4.13M4.94M97.05M-17.67M2.45M-684.00K41.04M35.39M180.47M79.57M
Gross Margin-25.65%47.99%100.00%40.80%-165.89%23.79%85.92%-2945.17%35.93%-5.93%71.23%14.82%90.83%52.23%
Operating Expense578.55K2.20M2.76M11.73M29.09M49.66M108.46M146.95M226.70M179.71M207.26M345.81M398.40M151.71M
Operating Income-832.73K-2.11M-2.57M-11.55M-33.22M-44.72M-11.41M-164.62M-224.25M-180.40M-166.22M-310.43M-217.92M-72.14M
Operating Margin-84.02%-1111.92%-1357.47%-2664.73%-1334.14%-215.29%-10.11%-27436.67%-3287.67%-1564.18%-288.48%-130.03%-109.67%-47.35%
EBITDA-1.32K-2.11M-2.52M-10.11M-24.53M-40.73M-7.05M-180.00M-213.07M-167.59M-149.34M-282.03M-181.97M-16.50M
EBITDA Margin-0.13%-1111.87%-1326.70%-2332.12%-985.17%-196.07%-6.24%-29999.50%-3123.68%-1453.15%-259.20%-118.14%-91.58%-10.83%
Net Income-834.04K-2.11M-2.57M-11.84M-33.29M-44.94M-13.24M-167.47M-226.79M-191.01M-172.23M-388.17M-266.22M127.24M
Net Income Margin-84.15%-1111.87%-1356.35%-2732.56%-1336.83%-216.34%-11.72%-27912.33%-3324.91%-1656.22%-298.91%-162.60%-133.98%83.52%
R&D----2.86M37.98M85.83M115.71M203.30M160.62M199.65M305.78M312.89M117.86M
R&D as % of Total Revenue----114.69%182.86%75.98%19285.50%2980.52%1392.69%346.50%128.09%157.47%77.36%
Interest Expense-01.56K294.41K204.55K129.00K1.75M1.46M691.00K2.64M2.58M2.27M36.02M16.40M
Interest Expense % of Total Revenue-0.00%0.82%67.92%8.21%0.62%1.54%242.83%10.13%22.86%4.48%0.95%18.13%10.76%

Balance Sheet

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets657.01K9.20M6.69M75.33M118.11M110.96M252.88M338.94M463.76M688.43M690.51M653.51M842.43M671.62M
Total Liabilities568.90K505.44K390.70K27.82M10.81M22.55M169.81M154.62M206.06M256.69M265.63M482.17M633.89M110.97M
Total Equity88.11K8.69M6.30M47.51M107.30M88.41M83.07M184.32M257.71M431.74M424.89M171.34M208.54M560.65M
Cash365.09K8.88M6.20M2.69M31.34M7.90M100.97M164.20M243.14M295.18M193.99M65.40M124.33M86.59M
Total Debt---4.06M4.29M1.12M49.72M9.44M6.26M44.38M38.22M231.48M191.72M58.31M
Net Debt-365.09K-8.88M-6.20M1.38M-27.05M-6.78M-51.25M-154.76M-236.88M-250.80M-155.77M166.08M67.39M-28.28M

Cash Flow

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--2.20M-2.67M-12.39M-39.43M-36.85M46.71M-148.59M-238.41M-219.61M-193.92M-406.68M-133.73M-250.69M
Investing Cash Flow---187.22K-1.13M-12.72M-3.35M-1.60M-1.19M-3.85M-77.35M-60.13M-16.77M-52.25M-37.14M
Financing Cash Flow-10.71M180.01K10.00M80.80M16.73M47.73M216.04M322.72M349.37M148.86M298.70M243.62M255.60M
Capital Expenditure00187.22K1.15M12.09M3.35M1.60M1.19M3.85M77.35M60.13M16.77M52.25M139.64M
Free Cash Flow--2.20M-2.86M-13.53M-51.51M-40.20M45.11M-149.78M-242.26M-296.96M-254.04M-423.45M-185.97M-390.33M
FCF to OCF-100.00%107.02%109.25%130.66%109.08%96.58%100.80%101.62%135.22%131.01%104.12%139.07%155.70%

Earnings

Report DateJun 30, 2016Nov 21, 2016Feb 27, 2017May 18, 2017Aug 31, 2017Nov 13, 2017Feb 28, 2018May 14, 2018Aug 24, 2018Nov 16, 2018Feb 22, 2019May 14, 2019Aug 23, 2019Nov 15, 2019Feb 28, 2020May 13, 2020Aug 21, 2020Nov 13, 2020Feb 26, 2021May 6, 2021Aug 13, 2021Oct 29, 2021Feb 24, 2022May 5, 2022Jul 22, 2022Oct 28, 2022Feb 17, 2023May 31, 2023Aug 29, 2023Nov 30, 2023Feb 26, 2024May 16, 2024Aug 28, 2024Oct 24, 2024Feb 20, 2025May 8, 2025Aug 26, 2025Oct 24, 2025Feb 19, 2026May 6, 2026Jul 20, 2026
EPS Estimate------------------358.99-2.19-380.00-330.00-289.73-2.32-330.47-405.76-161.29-171.24-156.73-221.68-382.80-413.66-11.25-0.04-3.625.10-3.4716.911.42-1.49--
EPS Actual-21.96-2.07-2.01-2.02-1.77-1.45-3.05-1.42-4.868.31-4.86-5.16-5.28-2.24-3.63-3.17-3.11-373.75-3.02-288.75-333.75-220.82-1.32-187.50-165.00-211.87-256.25-262.50-401.25-346.25-388.75-37.37-0.05-3.66-3.751.25-0.52-1.17-1.27-0.63-0.55
Surprise------------------4.11%-37.90%24.01%-1.14%23.78%43.10%43.26%59.34%-31.36%-49.64%-67.49%-81.00%9.55%6.02%-232.18%-25.00%-1.10%-173.53%136.02%-103.08%-182.39%14.77%--
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market-

Key Statistics & Ratios

Market Cap276.11M
Enterprise Value232.63M
Trailing P/E0.00
Forward P/E3.26
Price / Sales3.31
Price / Book0.41
EPS-3.28
Book Value26.15
Revenue (TTM)83.30M
Gross Profit (TTM)11.61M
EBITDA-61.34M
Profit Margin-90.04%
Operating Margin-5.99%
Return on Equity-16.02%
Return on Assets-5.83%
Shares Outstanding20.61M
Shares Float17.35M
Beta0.78
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 17, 20251:125